



Press release

Complix appoints Dr Thore Hettmann as Head of Therapeutic Development

Hasselt, October 17, 2011 – Complix NV, a biopharmaceutical company focused on the discovery and development of Alfabodies™, a novel class of protein therapeutics, announced today that it has appointed Dr Thore Hettmann as Head of Therapeutic Development. With this appointment Complix is further strengthening its management team as the Company is transitioning to its next level of development.

Dr Hettmann has more than 10 years experience in the biotech industry, with an excellent track record in the successful progression of biopharmaceutical product candidates into the clinical stage. At Complix he will be responsible for the preclinical and early clinical development of new Alfabody™ leads emerging from the discovery pipeline.

Prior to joining Complix Dr Hettmann was a Senior Director at U3 Pharma GmbH (Daiichi Sankyo, Germany), where he managed the development of several therapeutic antibodies from discovery up to early clinical testing. Previously he held senior R&D positions at EMD Lexigen Pharmaceuticals (Boston, MA), where he was in charge of preclinical development programs of conjugated antibodies and vaccines.

Dr Mark Vaeck, CEO of Complix, said: “We welcome Thore and are delighted that he is joining us to head up the therapeutic product development activities. His wealth of knowledge and expertise will be a valuable asset to the Company. The appointment of Thore comes at a timely moment and will accelerate our efforts to advance our first Alfabody™ drug candidates towards the clinic.”

Commenting on his appointment, Dr Hettmann said: “I am truly excited to join the Complix team, and I am looking forward to make an important contribution to the success of the Company. I am impressed by the potential of the Alfabody™ platform which enables to rapidly generate promising lead candidates against complex therapeutic targets. With this platform Complix is well positioned to create a portfolio of novel and competitive Alfabody™ therapeutics addressing important and underserved medical needs.”

About Complix:

Complix is a biopharmaceutical company engaged in the discovery and development of Alfabodies™, a novel and proprietary class of biopharmaceuticals with exceptional properties that offer significant advantages over existing protein based therapies. Alfabodies™ display a stability approaching that of small chemicals and the specificity of antibodies. They can bind with high affinity and selectivity to a wide range of disease targets, including targets or target epitopes that are difficult or impossible to address with



antibodies or other therapeutic protein classes. Due to their unique stability and versatility Alphabodies™ have the potential to be formulated for non-injectable routes of administration. Complix's R&D focus is on the development of novel Alphabody™ based therapies for autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease, and for viral diseases such as influenza, HIV and RSV.

Through the filing of several broad patent applications Complix has established a strong intellectual property position on its Alphabody™ platform and various applications. Because the Alphabody™ structure is totally unrelated to immunoglobulins, Alphabodies™ are independent of antibody based patent claims and offer a unique freedom-to-operate position. In 2010 Complix raised EUR 7 million through a Series A equity financing round, with Vesalius Biocapital, LRM and Crédit Agricole Private Equity as main investors. The Company is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. Complix has established a fully owned subsidiary in Luxembourg and has a strategic alliance with the public research institute CRP-Santé.

www.complix.com

Contacts

Complix NV

Dr. Mark Vaeck, CEO, +32 9 261 69 40

mark.vaeck@complix.com